Australian Government Accused of Misusing Funds to Combat E-Cigarettes

Sep.09.2022
Australian Government Accused of Misusing Funds to Combat E-Cigarettes
CAPHRA Coordinator Nancy Loucas criticizes Australian government's anti-vaping campaign as a misuse of public funds.

Nancy Loucas, the executive coordinator of the Asia Pacific Advocates for Tobacco Harm Reduction (CAPHRA), has expressed that the crackdown on e-cigarette retailers in Australia constitutes a serious misuse of public funds, which should be directed towards improving the country's healthcare system.


Before she issued her statement, the government of New South Wales in Australia intensified its warnings to compliant retailers about the risks associated with e-cigarette products. They also continue to back a controversial joint "education campaign" with the Department of Education on the issue of e-cigarettes.


The centerpiece of the event is the "Get the Facts" - Vaping Toolkit aimed at teachers, parents, and adolescent students. CAPHRA stated that despite Deputy Chief Health Officer Dr. Marianne Gale's assurance that the website does not contain "evidence-based resources and educational materials," it should be taken down while its many statements are independently verified.


These claims about electronic cigarettes are either completely exaggerated or, in the worst case scenario, have no scientific basis. The Australian public, regardless of age, needs to have complete confidence in any health statements on government websites. Unfortunately, this campaign is far from factual. Instead, it is filled with blatant lies," said Ms. Lucas.


In a statement that has angered advocates for tobacco harm reduction (THR) throughout the entire Asia-Pacific region, Dr. Gale claimed, "Many people believe that e-cigarettes are either completely harmless or less harmful than traditional cigarettes.


In a recent situation, an Australian chief health officer has been actively informing the public that the harm of vaping is not less than smoking. However, international research strongly refutes this claim. Despite providing no evidence to support her statement, the Australian public continues to receive such costly yet worthless advice. This is a complete embarrassment," she said.


According to CAPHRA, Australians who want to know the truth about vaping should look to New Zealand. Adults can legally use nicotine e-cigarettes there under regulations targeting retailers and manufacturers in 2020. Smokers looking to quit do not need to obtain a prescription from a doctor, unlike in Australia.


Asking doctors to prescribe cigarettes has left 2.3 million smokers in Australia disappointed, not to mention the approximately 20,000 Australians who die each year from smoking-related illnesses. While Australia's overall smoking rate has remained stagnant over the past decade, New Zealand has seen a 50% decrease in its smoking rate, largely due to the availability of legally sanctioned, less harmful alternatives for smokers, according to Ms. Lucas.


CAPHRA has pointed out that the headline of the New Zealand Ministry of Health's "Vaping facts" website states that "vaping is less harmful than smoking".


New Zealand is engaging in a positive dialogue with the public with the goal of achieving a smoke-free nation by 2025, with a smoking rate of 5% or less. In contrast, health leaders in Australia are continuing to ban adults from entering retail stores while using significant public resources to deter the use of e-cigarettes.


Australia's healthcare system is failing miserably. The persistent threats and lies surrounding e-cigarettes will make it almost impossible to achieve the country's goal of reducing smoking rates by 10% in the short term. They need a new strategy to eradicate tobacco, as the current one clearly isn't working," said Nancy Lucas.


CAPHRA, an advocacy group, has amassed almost 15,000 endorsement letters and is urging those who have quit smoking through the use of nicotine-free alternatives to share their stories on www.righttovape.org.


Statement:


This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.


This article does not represent the opinion of 2FIRSTS, and 2FIRSTS cannot confirm the truthfulness or accuracy of the article’s content. The compilation of this article is only intended for industry exchange and research purposes.


Due to limitations in the translation process, the translated article may not fully reflect the original text. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on all domestic, Hong Kong, Macao, Taiwan, and foreign-related statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Imperial Brands' NGP Revenue Rises 11.4% in FY2026 but Business Still Posts £63 Million Loss; Zone Reaches 114,000 US Stores as Smokeless Reporting Takes Shape
Imperial Brands' NGP Revenue Rises 11.4% in FY2026 but Business Still Posts £63 Million Loss; Zone Reaches 114,000 US Stores as Smokeless Reporting Takes Shape
Imperial Brands reported an 11.4% increase in next-generation product (NGP) net revenue to £419 million in fiscal 2026, while its adjusted NGP operating loss narrowed to £63 million. European NGP revenue rose 16.8%, while the Americas recorded a 17.1% decline. Global modern oral nicotine volumes increased 27.8%, with US nicotine pouch brand Zone expanding to approximately 114,000 stores. The company also acquired Black Buffalo in the US and Helwit in Sweden, broadening its oral nicotine portfolio. From FY2027, Imperial Brands will adopt a new Smokeless reporting category combining NGP with traditional oral tobacco. On the new basis, FY2026 Smokeless net revenue was £554 million, with adjusted operating profit of £14 million.
company
Nov.18
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
UK Vape Tax Reshapes Costs: VPZ's £1.5 Million Plan, Totally Wicked's Three HMRC Approvals and VSL's Wholesale Challenge
UK Vape Tax Reshapes Costs: VPZ's £1.5 Million Plan, Totally Wicked's Three HMRC Approvals and VSL's Wholesale Challenge
Britain's new vaping excise duty, introduced on October 1, 2026, is changing how manufacturers, distributors and retailers manage production, inventory and tax compliance. Specialist vape retailer VPZ reportedly plans to invest up to £1.5 million in production and duty-stamp systems, following earlier plans for a fifth production line, bonded warehousing and 40 additional stores. Rival Totally Wicked says it has obtained three HMRC approvals covering manufacturing, duty-suspended storage and representation of overseas manufacturers. Wholesale distributor Vape Supplier Limited (VSL) has identified stock conversion costs, warehousing requirements and margin pressure among its business risks. The companies illustrate how different operating models are responding to Britain's new tax and product-traceability requirements.
Market
Nov.16
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22